注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Allogene Therapeutics Inc是一家臨床階段的免疫腫瘤公司。該公司專注於用於治療癌症的基因工程同種異體T細胞療法的開發和推廣業務。該公司致力於利用蛋白質工程、基因編輯、基因插入和先進的T細胞製造技術開發多種同種異體嵌合抗原受體(CAR)T細胞候選產品。其先進的候選產品ALLO-501和ALLO-501A是工程化的靶向CD19的同種異體CAR T細胞療法。CD19是一種在B細胞細胞表面表達的蛋白質,是B細胞驅動的血液惡性腫瘤的有效靶點。它還正在開髮用於多發性骨髓瘤、透明細胞腎細胞癌(ccRCC)和其他血癌和實體瘤的工程化同種異體CAR T細胞候選產品。其主要候選產品包括ALLO-501、ALLO-501A、ALLO-715、ALLO-715、ALLO-605、ALLO-316和ALLO-647。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Joshua A. Kazam | 44 | 2017 | Co-Founder & Director |
Arie S. Belldegrun | 72 | 2017 | Co-Founder & Executive Chairman |
David D. Chang | 61 | 2018 | Co-Founder, President, CEO & Director |
John A. DeYoung | 58 | 2018 | Independent Director |
Matthew Porteus | 56 | - | Member of Scientific Advisory Board |
Antonius N.M. Schumacher | - | - | Chairman of Scientific Advisory Board |
Donald B. Kohn | - | - | Member of Scientific Advisory Board |
Malcolm K. Brenner | 69 | 2019 | Member of Scientific Advisory Board |
Todd B. Sisitsky | 51 | 2018 | Independent Director |
Franz Bernhard Humer | 76 | 2018 | Independent Director |
David Bonderman | 80 | 2018 | Lead Independent Director |
Deborah M. Messemer | 64 | 2018 | Independent Director |
Stephen J. Forman | 73 | 2019 | Member of Scientific Advisory Board |
Stephan A. Grupp | - | 2020 | Member of Scientific Advisory Board |
Jae Park | - | 2021 | Member of Scientific Advisory Board |
Thomas F. Gajewski | - | 2020 | Member of Scientific Advisory Board |
Stephen L. Mayo | 61 | 2022 | Independent Director |
Vicki L. Sato | 74 | 2021 | Independent Director |
Elizabeth A. Barrett | 61 | 2021 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核